Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02288325 · ClinicalTrials.gov registry record · Phase 4
A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder
A Phase 4 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 4
- Development phase
- 644
- Enrollment target
NCT02288325 is a Phase 4 study that has completed, run by Forest Laboratories. The registered enrollment target is 644 participants.
The verdict
NCT02288325, a Phase 4 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 644 participants
- Enrollment target
Study Summary
This study evaluates the efficacy, safety and tolerability of levomilnacipran extended-release (ER) compared with placebo in the prevention of depression relapse in major depressive disorder (MDD).
Interventions
- DRUG Placebo
- DRUG Levomilnacipran ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 644 participants |
| Start Date | 2014-11-18 |
| Est. Completion | 2016-09-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02288325
The ClinicalTrials.gov registry entry for NCT02288325 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 644 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02288325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02288325 about?
NCT02288325 is a clinical study titled "A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder". This study evaluates the efficacy, safety and tolerability of levomilnacipran extended-release (ER) compared with placebo in the prevention of depression relapse in major depressive disorder (MDD).
What is the current status of trial NCT02288325?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 644 participants. The study started on 2014-11-18. Estimated completion is 2016-09-16.
What interventions are being tested in trial NCT02288325?
The interventions under investigation include: Placebo (DRUG), Levomilnacipran ER (DRUG).
Who is sponsoring clinical trial NCT02288325?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.